Provided by Tiger Fintech (Singapore) Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc.

0.7824
+0.073410.35%
Post-market: 0.7577-0.0247-3.16%19:51 EDT
Volume:323.02K
Turnover:249.22K
Market Cap:36.57M
PE:-0.87
High:0.8000
Open:0.6969
Low:0.6958
Close:0.7090
Loading ...

BRIEF-Applied Therapeutics Appoints John H. Johnson As Executive Chairman

Reuters
·
20 Dec 2024

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

THOMSON REUTERS
·
20 Dec 2024

Applied Therapeutics Inc - Les Funtleyder Appointed Interim CEO

THOMSON REUTERS
·
20 Dec 2024

Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO

THOMSON REUTERS
·
20 Dec 2024

Reviva Pharmaceuticals Strengthens Financial Position with Offering

TipRanks
·
19 Dec 2024

Top Midday Decliners

MT Newswires Live
·
18 Dec 2024

Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering

Dow Jones
·
17 Dec 2024

Reviva Pharmaceuticals Prices $18 Million Public Offering

MT Newswires Live
·
17 Dec 2024

BRIEF-Reviva Prices $18 Mln Public Offering Of Common Stock And Warrants

Reuters
·
17 Dec 2024

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

THOMSON REUTERS
·
17 Dec 2024

Reviva Pharmaceuticals Holdings, Inc. - Offering Price $1.50 per Share With Series a and B Warrants

THOMSON REUTERS
·
17 Dec 2024

Reviva Pharmaceuticals Holdings, Inc. - Prices Public Offering of 12 Mln Shares

THOMSON REUTERS
·
17 Dec 2024

Press Release: Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

Dow Jones
·
17 Dec 2024

Reviva Pharmaceuticals announces common stock, warrant offering, no amount given

TIPRANKS
·
17 Dec 2024

Reviva Announces Proposed Public Offering

THOMSON REUTERS
·
17 Dec 2024

Reviva Announces Proposed Public Offering

GlobeNewswire
·
17 Dec 2024

Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia

MT Newswires Live
·
16 Dec 2024

BRIEF-Reviva Announces Preliminary Topline Data For The Long-Term Open Label Extension Portion Of The Phase 3 Recover Study Evaluating Brilaroxazine In Schizophrenia

Reuters
·
16 Dec 2024

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 Recover Study Evaluating Brilaroxazine in Schizophrenia

THOMSON REUTERS
·
16 Dec 2024

Reviva Pharmaceuticals- Full Data Set From Open-Label Extension (Ole) of Recover Expected in Q1 2025

THOMSON REUTERS
·
16 Dec 2024